+1 510.614.4550 info@mercatormed.com

Mercator is developing local and targeted micro-infusion solutions for diseases of the Peripheral Vasculature

Explore

Mercator Medsystems featured in BTIG’s Analyst Report: Medical Technology and Digital Health

Mercator is developing local and targeted micro-infusion solutions for diseases of the Peripheral Vasculature

Micro-infusion is the efficient delivery of drugs and biologics in aqueous form across vessel walls to provide targeted delivery in an interventional angiographic lab setting.

\

Local micro-infusion enables highly efficient therapy, avoiding off-target effects of systemic delivery

Micro-infusion gets therapeutic payload directly to diseases of interest

Improving physicians’ capability to match therapeutics to diseases

Clinical Trials Overview

The DEXTERITY trials are now enrolling.

DEXTERITY comprises two trials, one in acute DVT and one in subacute and chronic DVT, to reduce the chronic negative outcomes (post-thrombotic syndrome) associated with local inflammation.

The DEXTERITY-AFP and -SCI clinical trials will provide the critical evidence that local anti-inflammatory steroid delivery can improve outcomes in DVT treatment in the pelvis and thigh – the two anatomical regions hindered by poor chronic outcomes.

The DEXTERITY clinical trials have FDA IND, UK MHRA and Irish HPRA approvals.

Latest From Our Newsroom